Danone has taken legal action against Chobani in Manhattan federal court, alleging that the privately held U.S. company inflated protein claims on multi-serve tubs of Chobani 20G Protein and copied elements of Danone's product design. The French dairy group frames the confrontation as a defence of accurate nutrition labelling and as a response to what it calls aggressive competitive tactics that have allowed Chobani to undercut prices in the ultra-high-protein yoghurt segment.
The case centres on the way Chobani presents protein amounts on containers that hold multiple servings. Danone says that the labelling inflates the serving size and makes it difficult for consumers to make "an accurate comparison between products." In its statement the company said it believes consumers should be able to make product comparisons with "clear, accurate and consistent nutrition information."
Chobani rejected the claims. CEO Hamdi Ulukaya dismissed the lawsuit as publicity-seeking, saying Danone was "throwing things out there" and adding, "In a way, I am kind of laughing at it." Ulukaya also defended his firm's formulation: "We never add external protein to our products. We will never mislead anybody."
The dispute arrives amid a broader shift in U.S. consumer demand for protein-rich foods. According to research cited by Danone and industry analysts, yoghurt is one of a small set of items that has seen a more lasting increase in consumption among users of GLP-1 weight-loss medications. A consumer study by Boston Consulting Group found that, unlike some other protein products such as shakes, yoghurt tends to see ongoing demand gains both during use of these drugs and after patients stop them. Lauren Taylor, managing director and senior partner at BCG, summarized the trend: "High-protein foods like yoghurt or...meat seem to increase in frequency during and even more after stopping GLP-1s."
For Danone, which has publicly acknowledged difficulty in meeting surging consumer appetite for high-protein yoghurts in the second half of 2025, the stakes are both operational and strategic. The company is expanding production capacity, but investors and analysts are watching the recovery of its U.S. dairy business closely. Barclays analysts said in May that investors were becoming nervous over what they perceive as a lack of urgency around that recovery.
Market performance so far this year has reinforced those concerns. Danone's shares are down 15% year-to-date, compared with an 11% rise in the MSCI World Index. Barclays noted competitive dynamics that may explain investor unease: "Competitors, notably Chobani, (are) doing a much better job and growing currently at more than 20%." The bank added that "There is a feeling that Danone has been too slow to add capacity and perhaps it needs to spend more to compete with aggressive competitors such as Chobani."
Data shared by Chobani from NielsenIQ show the U.S. market share picture shifting in the last three years. Chobani reported a U.S. market share of 26% in the first quarter of this year, up from 21% three years earlier. Danone's share by contrast declined to 25.8% from 30.7% over the same period. Danone's own filings show its dairy unit achieved 3% like-for-like sales growth in the Americas in the first quarter of this year.
The legal clash is not the first between the two companies. Danone has sued Chobani at least four times since 2016, including a most recent action over coffee packaging slogans. Ulukaya said previous lawsuits had been dismissed. Observers in the sector expressed skepticism about the frequency of such disputes. Brad Charron, a former Chobani marketing executive who now runs plant-based protein brand ALOHA, said: "Danone sues Chobani four or five times a year for everything. If you can’t compete with them, sue them." He also noted that many large consumer packaged goods companies adjust serving sizes to present nutritional attributes such as protein differently, but added "at the end of the day, I think the consumer is smart enough to figure out whether they’re being misled one way or the other."
Beyond courtroom skirmishes, the case highlights the commercial pressure on established global players to respond rapidly to shifting demand patterns. Danone points to alleged copying and pricing tactics that it says harm its Oikos Pro brand, a product line it values at roughly billion euros, while Chobani emphasizes its growth in the U.S. market and rebuffs suggestions of misleading conduct.
As the dispute moves forward in federal court, it will be watched closely by competitors and investors alike for indications about label practices, pricing strategies and the pace of capacity investment in a protein-driven segment where consumer preferences are changing under the influence of weight-loss drug trends.
Sector impacts:
- Dairy and packaged food companies face intensified competition in protein-focused product lines.
- Retail pricing strategies and labelling standards are likely to come under scrutiny across consumer packaged goods.
- Investors in food companies are monitoring capacity expansion and U.S. market recovery plans closely.